<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083014</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2053</org_study_id>
    <nct_id>NCT04083014</nct_id>
  </id_info>
  <brief_title>Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia</brief_title>
  <acronym>RRAIHA01</acronym>
  <official_title>An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients of relapsed and refractory warm autoimmune hemolytic anemia or EVANS syndrome aged
      18 to 80 will be included in this study. The treatment regimen is a single dose anti-CD20
      antibody (500mg) combined with bortezomib (1.3mg/m2 twice a week for two weeks). The
      treatment course would be repeated three months later.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucocorticoids are the first-line treatment of warm AIHA. The overall response is 70-90%,
      but 10% to 20% patients are refractory to GCs and more than 50% patients will relapse after
      GCs tapering or cessation.

      Anti-CD20 monoclonal antibody is the preferred second-line treatment for relapsed refractory
      wAIHA. Anti-CD20 antibody 375 mg/m2, once a week, four times, is the standard treatment
      regimen. Low dose anti-CD20 antibody, 100mg once a week, four times, also showed similar
      response rate. However, the use of four times of intravenous infusion is trouble. So the
      investigators intend to explore the efficiency of the singe dose of 500mg anti-CD20 antibody.

      Anti-CD20 antibody takes median 6-8 weeks to response and only about 50% patients achieving
      long-term response. Plasma cells produce antibodies and long-lived plasma cells in bone
      marrow and spleen continuously work. Bortezomib is a proteasome inhibitor and targets plasma
      cells. Bortezomib has become a first-line treatment for clonal plasma cell diseases (such as
      multiple myeloma, systemic amyloidosis, POEMS syndrome, etc.). Bortezomib can also induce
      reactive plasma cell apoptosis and has a variety of immunomodulatory effects. The
      investigators try to combine bortezomib with anti-CD20 antibody, which may play a synergistic
      role and improve the efficacy.

      Patients of relapsed and refractory warm autoimmune hemolytic anemia or EVANS syndrome will
      receive a single dose anti-CD20 antibody (500mg) and bortezomib (1.3mg/m2 twice a week for
      two weeks) twice for three months interval.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">August 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response time</measure>
    <time_frame>two years</time_frame>
    <description>days hemoglobin increasing more than 20g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall response</measure>
    <time_frame>two years</time_frame>
    <description>total of complete response and partial response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>complete response</measure>
    <time_frame>two years</time_frame>
    <description>rate of achieving complete response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>relapse rate</measure>
    <time_frame>two years</time_frame>
    <description>relapse rate of responders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>two years</time_frame>
    <description>time duration of responders from first treatment to recurrence of decompensated hemolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>two years</time_frame>
    <description>time from first treatment to death of any causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>two years</time_frame>
    <description>side effects due to the combination of anti-CD20 antibody and bortezomib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <condition>Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment regimen is a single dose anti-CD20 antibody injection (500mg iv drip，day0) combined with bortezomib injection (1.3mg/m2 subcutaneous injection，twice a week for two weeks，day1，4，8，11). The treatment course will be repeated three months later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination of a single dose anti-CD20 antibody and bortezomib</intervention_name>
    <description>Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>Rituximab Injection</other_name>
    <other_name>Bortezomib for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of warm autoimmune hemolytic anemia or EVANS syndrome, primary or secondary.

          2. Patients refractory to glucocorticoids (HGB increase less than 20g/L after three weeks
             full dose glucocorticoids treatment). Or patients relapse after at least one course of
             glucocorticoids therapy (HGB &lt; 110g/L in female and HGB &lt; 120g/L in male). Or
             glucocorticoids dependence (prednisone maintenance dose &gt; 10mg a day). Or
             glucocorticoids intolerance.

          3. Normal heart function, liver function (total bilirubin &lt; 1.5×ULN, ALT, AST &lt; 3.0
             ×ULN), and renal function (serum creatinine &lt; 1.0 ×ULN).

          4. No active infection.

          5. No malignant tumors (except carcinoma in situ).

          6. Patients understand the content of the study, participate the study and sign the
             informed consent voluntarily.

        Exclusion Criteria:

          1. Patients with malignant tumors (excluding carcinoma in situ);

          2. With uncontrollable infections or other serious diseases;

          3. Active hepatitis B, serume HBV-DNA &gt; 104copies/ml;

          4. Women during pregnancy or lactation;

          5. Not strict contraception;

          6. Psychiatric patients and those with severe mental illness.

          7. Other conditions that researchers consider inappropriate to join the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Han</last_name>
    <role>Study Director</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miao Chen</last_name>
    <phone>+86 13520112578</phone>
    <email>chenm@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miao Chen</last_name>
      <phone>+86 13520112578</phone>
      <email>chenm@pumch.cn</email>
    </contact>
    <contact_backup>
      <last_name>Bing Han</last_name>
      <phone>+86 69155028</phone>
      <email>hanbingpumch@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010 Sep 16;116(11):1831-8. doi: 10.1182/blood-2010-03-259325. Epub 2010 Jun 14. Review.</citation>
    <PMID>20548093</PMID>
  </reference>
  <reference>
    <citation>Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese expert consensus on the diagnosis and treatment of autoimmune hemolytic anemia (2017) Red Blood Cell Disease (Anemia)]. Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):265-267. doi: 10.3760/cma.j.issn.0253-2727.2017.04.001. Chinese.</citation>
    <PMID>28468084</PMID>
  </reference>
  <reference>
    <citation>Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):382-389. doi: 10.1182/asheducation-2018.1.382. Review.</citation>
    <PMID>30504336</PMID>
  </reference>
  <reference>
    <citation>Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2009 Jan;9(1):201-9. doi: 10.1111/j.1600-6143.2008.02461.x. Epub 2008 Oct 31.</citation>
    <PMID>18976291</PMID>
  </reference>
  <reference>
    <citation>Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994 Sep 9;78(5):773-85.</citation>
    <PMID>8087845</PMID>
  </reference>
  <reference>
    <citation>Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, Daniel V, Naujokat C. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology. 2008 Jun;124(2):234-46. doi: 10.1111/j.1365-2567.2007.02761.x. Epub 2008 Jan 23.</citation>
    <PMID>18217957</PMID>
  </reference>
  <reference>
    <citation>Goldberg AL, Cascio P, Saric T, Rock KL. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol. 2002 Oct;39(3-4):147-64. Review.</citation>
    <PMID>12200047</PMID>
  </reference>
  <reference>
    <citation>Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H, Teh TC, Fleming S, Catalano JV, Chunilal SD, Johnston A, Opat SS, Shortt J. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv. 2016 Nov 22;1(1):31-35. doi: 10.1182/bloodadvances.2016001412. eCollection 2016 Nov 29.</citation>
    <PMID>29296693</PMID>
  </reference>
  <reference>
    <citation>Muhsen IN, Alahmari A, Alnahedh M, Alkhudair NA, Samarkandi H, El Fakih R. Bortezomib for immune thrombocytopenia and autoimmune hemolytic anemia. Hematol Oncol Stem Cell Ther. 2019 Jun 10. pii: S1658-3876(19)30051-2. doi: 10.1016/j.hemonc.2019.05.006. [Epub ahead of print]</citation>
    <PMID>31202670</PMID>
  </reference>
  <reference>
    <citation>Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS, Vital-Durand D, Lega JC. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2015 Apr;14(4):304-13. doi: 10.1016/j.autrev.2014.11.014. Epub 2014 Dec 9.</citation>
    <PMID>25497766</PMID>
  </reference>
  <reference>
    <citation>Danchaivijitr P, Yared J, Rapoport AP. Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol. 2011 Mar;86(3):331-2. doi: 10.1002/ajh.21950. Epub 2011 Jan 26.</citation>
    <PMID>21271614</PMID>
  </reference>
  <reference>
    <citation>Hosoba S, Jaye DL, Cohen C, Roback JD, Waller EK. Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion. 2015 Feb;55(2):259-64. doi: 10.1111/trf.12815. Epub 2014 Aug 25. Review.</citation>
    <PMID>25156334</PMID>
  </reference>
  <reference>
    <citation>Cao L, Koh LP, Linn YC. Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib. Leuk Lymphoma. 2018 Oct;59(10):2500-2502. doi: 10.1080/10428194.2017.1421759. Epub 2018 Jan 18.</citation>
    <PMID>29345206</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 31, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Chen Miao</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>warm autoimmune hemolytic anemia</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>EVANS syndrome</keyword>
  <keyword>anti-CD20 monoclonal antibody</keyword>
  <keyword>bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patients age,gender,diagnosis,treatment details, efficiency and survival.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will become available 6 months after the publication of the study and for 2 years.</ipd_time_frame>
    <ipd_access_criteria>get permission from the researchers.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

